Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5 , Pages 943-950 , May 2009

Outcome of Surgical Management of Bisphosphonate-Related Osteonecrosis of the Jaws: Review of 33 Surgical Cases

A part of these data were presented in preliminary abstract form at the American Association of Oral and Maxillofacial Surgeons 88th Annual Meeting, San Diego, CA.

  • David C. Stanton, DMD, MD

      Affiliations

    • Associate Professor and Residency Program Director, Department of Oral and Maxillofacial Surgery, University of Pennsylvania Health System and School of Dental Medicine, Philadelphia, PA
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Stanton: Department of Oral and Maxillofacial Surgery, University of Pennsylvania School of Medicine, 3400 Spruce Street, 5th Floor, White Building, Philadelphia, PA 19104
    • ,
  • Edward Balasanian, DDS, MD

      Affiliations

    • Formerly, Chief Resident, University of Pennsylvania Health System and School of Dental Medicine, Philadelphia, PA; and Currently, Private Practice, Newport Beach, CA

References 

  1. Marx R, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis-osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567
  2. Hellstein J, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63:682
  3. Ruggiero S, Mehrota B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2005;62:527
  4. AAOMS Board of Trustees. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws, 9-25-2006. J Oral Maxillofac Surg. 2007;65:369
  5. AAOMS Board of Trustees. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. AAOMS Website: www.aaoms.org/docs/position_papers/osteonecrosis.pdf9-25-2006Accessed October 9, 2006
  6. Hellstein J, Fielding C. Bisphosphonate osteochemonecrosis: Clinical findings and treatment theories may relate to a possible analogy with “phossy” jaw (Essay Program 1, 4/18/2005). www.aaomp.org/general/2005_Essays.pdfAccessed March 22, 2007
  7. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63:682
  8. Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: Bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg. 2004;62:1563
  9. Marx RE, Stern D. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. In: Chicago, IL: Quintessence Publishing; 2003;p. 36–39
  10. Marx RE. Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41:283
  11. Marx RE. A new concept in the treatment of osteoradionecrosis. J Oral Maxillofac Surg. 1983;41:351
  12. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Chicago, IL: Quintessence Publishing; 2007;
  13. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  14. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  15. Bradley JC. Radiological investigation into the age changes of the inferior dental artery. Br J Oral Surg. 1975;13:82
  16. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharma Design. 2003;9:2643

 David C. Stanton is a consultant for a law firm, on behalf of Novartis, the manufacturer of Aredia and Zometa.

PII: S0278-2391(09)00116-5

doi: 10.1016/j.joms.2008.12.057

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5 , Pages 943-950 , May 2009

Article Tools

* Image Usage & Resolution